LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

G-Branch™ Thoracoabdominal Artery Stent Graft System Obtained Official Registration Approval from the China NMPA

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 6 November 2025, the G-Branch™ thoracoabdominal artery stent graft system ("**G-Branch™**" or the "**Product**"), a device jointly developed by Professor Guo Wei's team from the First Medical Centre of the Chinese PLA General Hospital and the Group, obtained official registration approval from the China National Medical Products Administration ("**NMPA**"). The Product is indicated for the treatment of thoracoabdominal aortic aneurysms ("**TAAA**") involving the celiac trunk, superior mesenteric artery, and bilateral renal arteries, which could achieve total endovascular repair of thoracoabdominal aortic aneurysms.

According to publicly available data from Frost & Sullivan, the number of aortic aneurysm patients in China is expected to exceed one million by 2030. With the aging and improvement of health awareness, the incidence rate and detection rate of aortic aneurysm will still rise. Among them, TAAA is one of the most complex and high-risk types of aortic aneurysm due to its involvement of the celiac trunk, superior mesenteric artery, and bilateral renal arteries. Once the aneurysm ruptures, the mortality rate of patients can reach up to 95%. Traditional open surgery has

extremely high risks and huge trauma. The thoracoabdominal incision can be as long as 1 meter, and the surgery takes 12 hours. The whole body is sutured with over 1,000 stitches, and the postoperative recovery period of patients is long, and the postoperative complication rate is as high as 30%.

The Product adopts the world's first "double inner branches and double outer branches" hybrid branch design. The upper and lower segments of the stent differ in diameter. The four branches are positioned almost on the same level, corresponding precisely to the anatomical origins of the visceral arteries. This design enables complete endovascular branch reconstruction while maintaining continuous intraoperative perfusion of vital organs.

In 2021, the Product was accepted into the National Special Examination and Approval Procedure for Innovative Medical Devices, referred to as the "Green Channel", and its innovation was formally recognised by national authorities. To fully validate the clinical value of G-Branch™, the Company have successively conducted the GUARANTEE-1, GUARANTEE-2 and GUARD series of clinical studies to comprehensively evaluate the safety and efficacy of G-Branch™ for TAAA and thoracoabdominal aortic dissection aneurysm ("**TADA**").

GUARANTEE-1 Study

The GUARANTEE-1 study was a prospective, multicenter, single-arm pivotal clinical study, led by Professor Guo Wei as the principal investigator (PI), that aimed to evaluate the safety and efficacy of G-Branch™ for the treatment of TAAA. The study enrolled 73 TAAA patients across 14 centers, with the following results of the study:

- the branch artery reconstruction success rate reached 99.7%;
- the technical success rate reached 95.9%;
- the 12-month branch vessel patency rate reached 96.7% (cumulative patency rate);
- the overall survival rate reached 98.6%; and
- the 30-day post-procedural major adverse event (MAE) rate was as low as 5.5%.

The clinical results of the GUARANTEE-1 study were published in August 2025 in the prestigious International Journal of Surgery, reflecting the international academic community's high regard for China's original clinical research and demonstrating China's innovative strength in the field of endovascular aortic treatment.

GUARANTEE-2 Study

The GUARANTEE-2 study was a prospective, single-center clinical study that enrolled 69 TAAA patients, among whom 31 subjects completed the 12-month computed tomography angiography ("**CTA**") follow-up. The interim results of the study were as follows：

- Type I/III endoleak rate during the twelve months after surgery, 0%;
- aneurysmal enlargement rate during the twelve months after surgery, 0%;
- stent migration rate during the twelve months after surgery, 0%; and
- artery patency rate during the twelve months after surgery, 99.18%.

GUARD Study

The GUARD study was a prospective, single-center first-in-man ("**FIM**") study designed to evaluate the safety and efficacy of G-Branch™ for the treatment of TADA. The results of the study were as follows:

- Type I/III endoleak rate during the twelve months after surgery, 0%;
- aneurysmal enlargement rate during the twelve months after surgery, 0%;
- stent migration rate during the twelve months after surgery, 0%; and
- artery patency rate during the twelve months after surgery, 96.43%.

Collectively, the three studies have demonstrated that G-Branch™ has achieved international leading standards in both safety and efficacy. To date, over 200 successful clinical implantations of G-Branch™ have been performed in major countries including Germany, Italy, Switzerland and Greece, which has made G-Branch™ earn wide recognition and high praise from international vascular specialists for its outstanding performance and innovation.

The Group possesses independent intellectual property rights for the Product, which is expected to provide TAAA patients with a systematic solution enabling total endovascular repair of visceral branches. This solution is entirely interventional, with anticipated advantages of less trauma, simpler operation and easier adaptation.

Following the approval and launch of the Aortic Arch Stent Graft System and Aortic Stent Graft System in the first half of 2025, the Product has also been approved for marketing, thus further enriching the Company's portfolio in the peripheral vascular intervention field and making the Company one of the first innovative enterprises with integrated solutions for complete endovascular aortic repair in the world. As commercialisation progresses, the Company will provide a solution for the total endovascular repair of thoracoabdominal aortic aneurysms that is more flexible, comprehensive, safe and effective, and easy to operate. Furthermore, in collaboration with industry experts, the Company will advance the development and commercialisation of additional medical device products that are urgently needed in clinical practice, thereby driving the Group's growth in the medical device field and benefiting a wide range of patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 6 November 2025

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.